Internal Nanobodies Tackle Cystic Fibrosis

InnovationHealthcareInternal Nanobodies Tackle Cystic FibrosisByWilliam A. Haseltine,Contributor.Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicineFollow AuthorMay 11, 2026, 10:49am EDT--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more.A cell-penetrating nanobody restores function in cystic fibrosis—and points to a new class of intracellular medicines.ACCESS Health InternationalAntibody drugs have reshaped modern medicine over the past several decades, especially in diseases like cystic fibrosis. Early progress came from identifying the genetic mutations behind the condition, followed by therapies that partially correct the faulty protein. While these treatments improve outcomes, they do not fully restore normal function. The latest advance pushes this progress further by extending the reach of antibody-based technology inside the cell, where many disease processes actually begin.This approach uses a nanobody—a smaller, more compact antibody fragment—since full antibodies cannot cross the cell membrane and instead bind only to targets on the cell surface. The nanobody enters cells and stabilizes a mutated cystic fibrosis protein from within, helping it function properly. In cystic fibrosis, the protein that regulates salt and water transport is misshapen, and current drugs improve its folding or activity but do not fully correct it. Earlier efforts explored intracellular nanobodies using engineered systems, including AI-guided designs, but the central challenge remains: delivering a protein into cells in an active form. Here, that challenge is addressed by enabling the nanobody itself to cross the membrane.New research builds on precision protein targeting and membrane transport by combining a nanobody with a molecular tag designed to carry it across the cell membrane. This hybrid molecule reaches an intracellu...